Key result
A baseline resting heart rate below 82 bpm in patients with precapillary pulmonary hypertension was associated with a significantly longer overall event-free survival compared to a heart rate of 82 bpm or higher (2409 vs. 1332 days).
Why the study?
Does a resting heart rate < 82 bpm at diagnosis predict better event-free survival in patients with pulmonary arterial and chronic thromboembolic pulmonary hypertension?
Observational (n=206)
No
Does a resting heart rate < 82 bpm at diagnosis predict better event-free survival in patients with pulmonary arterial and chronic thromboembolic pulmonary hypertension?
A resting heart rate below 82 bpm at diagnosis is a strong, independent predictor of longer transplant-free survival in patients with PAH and inoperable CTEPH.
Answers are grounded in this paper and cite their sources.
Supports resting HR <82 bpm for risk stratification in precapillary PH; leaves open whether lowering HR improves outcomes.
BACKGROUND: A low resting heart rate (HR) is prognostically favourable in healthy individuals and in patients with left heart disease. In this study we investigated the impact of HR at diagnosis on long-term outcome in patients with differently classified precapillary pulmonary hypertension (pPH). METHODS: pPH patients diagnosed as pulmonary arterial (PAH) or inoperable chronic thromboembolic pulmonary hypertension (CTEPH) were registered and regularly followed at our centre Baseline characteristics and events defined as either death or lung transplantation were noted. The prognostic value of HR was analysed using Kaplan Meier estimates, live tables and Cox regression. RESULTS: 206 patients with PAH (148) and inoperable CTEPH (58) were included. The median HR was 82 bpm. pPH with a HR below 82 bpm had a significantly longer overall event-free survival (2409 vs.1332 days, p = .000). This advantage was similarly found if PAH and CTEPH were analysed separately. Although a lower HR was associated with a better hemodynamic and functional class, HR was a strong and independent prognostic marker for transplant free survival even if corrected for age, sex, hemodynamics and functional status. CONCLUSION: We show that resting HR at diagnosis is a strong and independent long-term prognostic marker in PAH and CTEPH. Whether reducing HR by pharmacological agents would improve outcome in pPH has to be assessed by future trials with high attention to safety.
No takes yet. Share an insight, caveat, or question.
Hildenbrand et al. (2012) conducted an observational in Precapillary pulmonary hypertension (PAH and inoperable CTEPH) (n=206). Resting heart rate < 82 bpm vs. Resting heart rate ≥ 82 bpm was evaluated on Overall event-free survival (death or lung transplantation) (p=<0.001). A baseline resting heart rate below 82 bpm in patients with precapillary pulmonary hypertension was associated with a significantly longer overall event-free survival compared to a heart rate of 82 bpm or higher (2409 vs. 1332 days).
Synapse has enriched 10 related papers. Consider them for comparative context: